Lupin Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Lupin Ltd filed with BSE on 12 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Lupin reported record quarterly revenue exceeding INR 8,000 crores and EBITDA exceeding INR 2,400 crores, marking the 16th consecutive quarter of YoY growth. Management attributed growth to strong U.S. sales, ex-U.S. organic growth of over 20% YoY, and double-digit growth across India, Other Developed Markets, and Emerging Markets. Management reiterated full-year guidance of high single-digit revenue growth with EBITDA margins of around 25%, while flagging increased competitive intensity on key U.S. products in coming quarters.
Numbers mentioned
Total revenue from operations: INR 8,277 crores (Q1 FY27)
p. 5
“total revenue from operations growing 32% YoY to INR 8,277 crores”
Ramesh Swaminathan, page 5 of the filed PDF · View the filing
EBITDA excluding forex and other income: INR 2,464 crores (Q1 FY27)
p. 5
“EBITDA excluding forex and other income growing at strong 50% YoY to INR 2,464 crores”
Ramesh Swaminathan, page 5 of the filed PDF · View the filing
U.S. business sales: USD 366 million (Q1 FY27)
p. 5
“the U.S. business recorded sales of USD 366 million, 30% higher YoY in constant currency terms”
Ramesh Swaminathan, page 5 of the filed PDF · View the filing
India business sales: INR 2,380 crores (Q1 FY27)
p. 6
“the India business recorded sales of INR 2,380 crores, growing 13.9% YoY”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
India core prescription business growth: 15.1% YoY (Q1 FY27)
p. 6
“the core prescription business grew 15.1% YoY as against IPM growth of 13.5%, translating to 1.1x IPM growth”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
Other Developed Markets sales: INR 1,149 crores (Q1 FY27)
p. 6
“our Other Developed Markets, Europe, Canada, and Australia recorded sales of INR 1,149 crores growing 48% YoY and accounting for 14% of our total sales”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
Emerging markets sales: INR 990 crores (Q1 FY27)
p. 6
“emerging markets recorded sales of INR 990 crores, delivering an impressive 52% YoY growth led by markets in Brazil, South Africa, and Philippines”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
Gross margins: 74.6% (Q1 FY27)
p. 7
“This quarter was at 74.6% up from 71.3% in Q1FY26 last year”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
R&D spend: INR 608 crores, 7.4% of sales (Q1 FY27)
p. 7
“R&D at INR 608 crores is 7.4% of sales in Q1FY27, as compared to INR 498 crores at 8.1% of sales in Q1FY26”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
EBITDA margin: 30% (Q1 FY27)
p. 7
“Margins were 30% vis-a-vis 26.6% last year in the same period, an increase of 340 basis points over the last year”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
Effective tax rate: 29.8% (Q1 FY27)
p. 7
“The effective tax rate stood at 29.8% for the quarter”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
Operating Working Capital: INR 8,260 crores (as of 30 June 2026)
p. 8
“The Operating Working Capital was INR 8,260 crores as of 30 June '26 as compared to INR 7,132 crores as of 31 March '26”
Ramesh Swaminathan, page 8 of the filed PDF · View the filing
Net cash: INR 2,831 crores (as of 30 June 2026)
p. 8
“Net cash stood at INR 2,831 crores as of 30 June vis-a-vis INR 4,636 crores as of 31 March quarter, largely due to closure of our VISUfarma acquisition”
Ramesh Swaminathan, page 8 of the filed PDF · View the filing
ROCE: 29.5% (Q1 FY27)
p. 8
“ROCE for the company translates to 29.5% vis-a-vis 28.4% as at end of FY26”
Ramesh Swaminathan, page 8 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Full-year revenue growth — high single-digit · FY27
stated firmly by Vinita Gupta
p. 5
“We would like to reiterate our earlier guidance of high single-digit revenue growth for the organization with EBITDA margins of around 25% during the year.”
Vinita Gupta, page 5 of the filed PDF · View the filing
U.S. business revenue — USD 1.1 billion to USD 1.2 billion · FY27
stated firmly by Vinita Gupta
p. 3
“For the full year, we expect the U.S. business to be in the USD 1.1 billion to USD 1.2 billion range, aided by growth in base business, our injectable launches, and contribution from Pegfilgrastim offsetting the additional competition in products like Mirabegron and Tolvaptan during the year.”
Vinita Gupta, page 3 of the filed PDF · View the filing
U.S. business growth trajectory — FY28
stated as an aspiration by Vinita Gupta
p. 3
“We believe that all these initiatives should help in the U.S. getting back to its growth trajectory from FY28 onwards.”
Vinita Gupta, page 3 of the filed PDF · View the filing
U.S. quarterly revenue — USD 250 million to USD 280 million a quarter · next couple of quarters
stated conditionally by Vinita Gupta
p. 9
“We expect revenues to be anywhere between USD 250 million to USD 280 million a quarter over the next couple of quarters.”
Vinita Gupta, page 9 of the filed PDF · View the filing
India business outperformance vs IPM — 1.2x to 1.3x IPM
stated as an aspiration by Vinita Gupta
p. 4
“We remain confident that our India formulations business will continue to outperform IPM by 1.2x to 1.3x, supported by our strong India prescription sales force of nearly 11,300 people and pipeline of more than 80 new product launches over the coming years.”
Vinita Gupta, page 4 of the filed PDF · View the filing
Chronic segment share of India portfolio — 70% · next five years
stated as an aspiration by Vinita Gupta
p. 3
“we have set ourselves a target to increase the share to 70% in the next five years”
Vinita Gupta, page 3 of the filed PDF · View the filing
India novel proprietary products share of revenue — one third of India revenues · next 10-year timeframe
stated as an aspiration by Vinita Gupta
p. 4
“We have set ourselves a target of novel proprietary products contributing one third of our India revenues in the next 10-year timeframe.”
Vinita Gupta, page 4 of the filed PDF · View the filing
R&D spend as % of sales — around 8% · FY27
stated firmly by Ramesh Swaminathan
p. 7
“For the full-year, R&D is expected to be around 8%.”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
EBITDA margin — around 25% · FY27
stated firmly by Ramesh Swaminathan
p. 7
“For the full year, as indicated by Vinita, we expect EBITDA margins to be around the 25% mark.”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
Effective tax rate — 27% - 28% · FY27
stated firmly by Ramesh Swaminathan
p. 7
“For the full-year, however, we expect it to be in the region of 27% - 28%.”
Ramesh Swaminathan, page 7 of the filed PDF · View the filing
EBITDA margin (revised) — 24% to 25% · FY27
stated conditionally by Ramesh Swaminathan
p. 10
“we are being a little more cautious when you speak about the fact that the EBITDA margins would be in the range of 24% to 25%”
Ramesh Swaminathan, page 10 of the filed PDF · View the filing
U.S. FTF and product launches — 50 plus products including 10 exclusive first-to-files, five biosimilars, two to three 505(b)(2)s · next three years
stated firmly by Vinita Gupta
p. 3
“In the next three years, we expect to launch 50 plus products in the U.S. with 10 exclusive first-to-files, five biosimilars, as well as two to three 505(b)(2)s.”
Vinita Gupta, page 3 of the filed PDF · View the filing
Product filings this year — more than 15 products including at least seven in Respiratory · FY27
stated firmly by Vinita Gupta
p. 3
“We are planning to file more than 15 products this year, including at least seven in the Respiratory segment.”
Vinita Gupta, page 3 of the filed PDF · View the filing
India product launches — about 20 products · FY27
stated firmly by Ramesh Swaminathan
p. 6
“We have launched around seven products in Q1FY27 and plan to launch about 20 products in FY27, vis-a-visa 15 products which we have launched in FY26.”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
Innovative proprietary products in India — USD 1 billion or one-third of business · next 10 years
stated as an aspiration by Nilesh Gupta
p. 14
“The goal of USD 1 billion or one-third of our business to come from innovative products is an aspiration for the next 10 years.”
Nilesh Gupta, page 14 of the filed PDF · View the filing
Innovative product launches in India — 60 to 70 launches · next 10 years
stated as an aspiration by Nilesh Gupta
p. 14
“So, over a period of the next 10 years, we're looking at 60 to 70 launches of the innovative products.”
Nilesh Gupta, page 14 of the filed PDF · View the filing
Complex generics portfolio — doubling · next three to five years
stated as an aspiration by Vinita Gupta
p. 17
“Overall, we are looking at our portfolio from the complex generics doubling over the next three to five years.”
Vinita Gupta, page 17 of the filed PDF · View the filing
Other Developed Markets growth — 10% to 20% · next couple of years
stated conditionally by Vinita Gupta
p. 17
“We are looking at potentially double-digit growth, in some years., higher than others, but anywhere between 10% to 20% over the next couple of years.”
Vinita Gupta, page 17 of the filed PDF · View the filing
Adjacencies EBITDA drag — future quarters
stated as an aspiration by Ramesh Swaminathan
p. 16
“But clearly, that would be a thing of the past in quarters to come.”
Ramesh Swaminathan, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Yes, confirmed over the FY27 base.
Answered by Vinita Gupta
Asked by Damayanti Kerai: Is the FY28 return to U.S. growth trajectory based on the FY27 base of USD 1.1-1.2 billion?
p. 8
“That’s right. Over the FY27 base.”
Vinita Gupta, page 8 of the filed PDF · View the filing
Additional competition from Apotex, Teva and a potential new entrant in Tolvaptan from Q2 and September, plus full-quarter impact of Mirabegron pressure, will reduce revenues.
Answered by Vinita Gupta
Asked by Shyam Srinivasan: Why is U.S. quarterly revenue expected to step down from Q1 levels to guidance range?
p. 9
“We expect Tolvaptan to come down over the next couple of quarters. Mirabegron has already seen pressure in the first quarter, and we expect that to be a full quarter impact from Q2 onwards.”
Vinita Gupta, page 9 of the filed PDF · View the filing
Gross margin will depend on Tolvaptan realization and pricing impacts, plus inventory versus cost increases from geopolitical tensions.
Answered by Ramesh Swaminathan
Asked by Shyam Srinivasan: What is a normalized gross margin given the 25% full-year EBITDA margin guidance versus 75% gross margin this quarter?
p. 10
“we are being a little more cautious when you speak about the fact that the EBITDA margins would be in the range of 24% to 25%”
Ramesh Swaminathan, page 10 of the filed PDF · View the filing
Management expects a longer market share tail due to specialty pharmacy and REMS program dynamics, but will cede some share to new entrants.
Answered by Vinita Gupta
Asked by Neha Manpuria: Can Lupin defend Tolvaptan market share against new entrants?
p. 10
“We would expect the market share tail to be longer, because of the fact that it's a specialty pharmacy product as well as our REMS program.”
Vinita Gupta, page 10 of the filed PDF · View the filing
These adjacencies are currently contributing roughly 1-1.5% negative impact on EBITDA margin.
Answered by Ramesh Swaminathan
Asked by Vivek Agarwal: What is the EBITDA margin drag from loss-making adjacency businesses like Diagnostics, Digital, OTC and CDMO?
p. 16
“Overall about 1% - 1.5%.”
Ramesh Swaminathan, page 16 of the filed PDF · View the filing
Goal date for approval is September, with commercial quantities building from January 2027 and launch expected in summer with 10-12 months before generic competition.
Answered by Vinita Gupta
Asked by Kunal Dhamesha: What is the timeline for Apixaban 505(b)(2) approval and launch?
p. 15
“We have a goal date of September. We are hoping that we get approval in September, and then simultaneously we're building up launch quantities.”
Vinita Gupta, page 15 of the filed PDF · View the filing
Risks flagged
Increased competitive intensity on major U.S. products Mirabegron and Tolvaptan
p. 5
“we anticipate some moderation in performance during the remainder of the year, especially in the U.S. from increased competitive intensity on our two major products”
Vinita Gupta, page 5 of the filed PDF · View the filing
Uncertain geopolitical environment
p. 5
“We are closely monitoring the potential headwinds from an uncertain geopolitical environment as well.”
Vinita Gupta, page 5 of the filed PDF · View the filing
Lower tender sales in India GIB business offsetting core prescription growth
p. 6
“This is offset by lower tender sales in our GIB business in India.”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
Lower growth in Respiratory segment in India versus category
p. 6
“This is offset by lower growth in Respiratory segment which grew 6.9% as against category growth of 11.3%.”
Ramesh Swaminathan, page 6 of the filed PDF · View the filing
Higher input costs from geopolitical tensions impacting gross margins going forward
p. 10
“the impact of price increases that we have seen in the recent past; post the cost increase that is because of the geopolitical tensions around”
Ramesh Swaminathan, page 10 of the filed PDF · View the filing
Volatility in quarterly EBITDA margins due to product transitions and competition
p. 16
“There will be volatility between quarters, for sure.”
Ramesh Swaminathan, page 16 of the filed PDF · View the filing
Loss-making adjacency businesses currently dragging on EBITDA margin and EPS
p. 16
“all of these are at this stage loss making and therefore is impacting EBITDA margins and of course, our overall EPS at this stage”
Ramesh Swaminathan, page 16 of the filed PDF · View the filing
European healthcare budgets under pressure limiting access for innovative products
p. 12
“we are seeing all the major European markets really struggling with the overall healthcare budgets, the overall drug spends budgets, and they are struggling to really bring more innovative products into the fold”
Vinita Gupta, page 12 of the filed PDF · View the filing
Germany doubling rebate requirements on part of portfolio
p. 12
“even in Germany, on the one side, you see the increase in rebate on a part of our portfolio”
Vinita Gupta, page 12 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.